Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis

ABSTRACT:

Background:

Patients with relapsed/refractory multiple myeloma (RRMM) usually have dismal prognostic outcomes. Venetoclax, a selective inhibitor of antiapoptotic protein B-cell lymphoma-2 (BCL-2), demonstrates antimyeloma activity in plasma cells with t(11;14) or high BCL-2 expression.

Objectives:

This meta-analysis aimed to investigate the efficacy and safety of venetoclax-based therapy in RRMM.

Design:

This is a meta-analysis study.

Data Sources and Methods:

PubMed, Embase, and Cochrane were searched for studies published up to 20 December 2021. Overall response rate (ORR), rate of very good partial response or better (≧VGPR), and complete response (CR) rate were pooled with the random-effects model. Safety was evaluated by the incidences of grade ≧3 a

SUBMITTER:  

PROVIDER: S-EPMC9989383 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature